DataSheet_1_Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: A case report.docx

We report the fourth described case of severe toxic rhabdomyolysis occurring in an 81-year-old woman caused by the concomitant administration of palbociclib taken at the usual dosage (125 mg per day) and simvastatin. To the best of our knowledge, this is the first reported case successfully treated by plasma exchanges, with complete functional recovery within two months. The severity of this case justifies further consideration of pharmacokinetic interactions between palbociclib or other CDK-4-6 inhibitors and statins, which potentially increase the risk of an adverse event.

本研究报道第4例由常规剂量（每日125mg）帕博西尼（palbociclib）与辛伐他汀（simvastatin）联合给药诱发的重度中毒性横纹肌溶解症病例，患者为81岁女性。据我们所知，该病例是首项经血浆置换（plasma exchange）成功治疗、并在2个月内实现完全功能恢复的报道案例。本病例的严重程度提示，有必要进一步探究帕博西尼或其他CDK-4-6抑制剂与他汀类药物之间的药代动力学相互作用，此类相互作用或可升高不良事件的发生风险。